Eisler Capital (Us) LLC Eli Lilly & CO Call Options Transaction History

Eisler Capital (Us) LLC

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$772.14 - $960.02 $1.7 Million - $2.11 Million	2,200 Added 40.0%	7,700 $6.82 Billion
Q2 2024 Aug 13, 2024	BUY	$724.87 - $909.04 $434,922 - $545,424	600 Added 12.24%	5,500 $4.98 Billion
Q1 2024 May 14, 2024	BUY	$592.2 - $792.28 $2.9 Million - $3.88 Million	4,900 New	4,900 $3.81 Billion
Q3 2023 Nov 13, 2023	BUY	$434.7 - $599.3 $738,990 - $1.02 Million	1,700 Added 7.0%	26,000 $14 Billion
Q2 2023 Aug 14, 2023	BUY	$350.74 - $468.98 $8.52 Million - $11.4 Million	24,300 New	24,300 $11.4 Billion

4,011

751M

8.27M

10.5M

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $756B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

Get notified when there are updates to the investment portfolio of Eisler Capital (Us) LLC, based on Form 13F filings with the SEC.

Stay updated on Eisler Capital (Us) LLC with notifications on news.